MAPK-induced Ser727 phosphorylation promotes SUMOylation of STAT1.

Biochem J

Institute of Medical Technology, University of Tampere, FIN-33014 Tampere, Finland.

Published: January 2008

STAT1 (signal transducer and activator of transcription 1) is a critical mediator of IFN-gamma (interferon-gamma)-induced gene responses, and its function is regulated through phosphorylation of Tyr701 and Ser727. MAPK (mitogen-activated protein kinase) pathways mediate phosphorylation of Ser727 in response to microbial infections, stress stimuli and growth factors. Recently, STAT1 was found to become modified by PIAS (protein inhibitor of activated STAT)-mediated SUMO-1 (small ubiquitin-related modifier-1) conjugation at Lys703, but the regulation of this modification is largely unknown. Here, we have investigated the role of MAPK-induced Ser727 phosphorylation in regulation of STAT1 SUMOylation. Activation of the p38MAPK pathway by upstream activating kinase, MKK6 (MAPK kinase-6) or osmotic stress enhanced the SUMOylation of STAT1, which was counteracted by the p38MAPK inhibitor SB202190 or by dominant-negative p38MAPK. Activation of the ERK1/2 (extracellular-signal-regulated kinase 1/2) pathway by Raf-1 also enhanced Ser727 phosphorylation and SUMOylation of STAT1, and this induction was counteracted by PD98059 inhibitor. Mutation of Ser727 to alanine abolished the p38MAPK-induced SUMOylation. Furthermore, S727D and S727E mutations, which mimic the phosphorylation of Ser727, enhanced the basal SUMOylation of STAT1 and interaction between PIAS1 and STAT1. Taken together, these results identify Ser727 phosphorylation as a regulator of STAT1 SUMOylation and highlight the central role of Ser727 in co-ordination of STAT1 functions in cellular responses.

Download full-text PDF

Source
http://dx.doi.org/10.1042/BJ20070620DOI Listing

Publication Analysis

Top Keywords

ser727 phosphorylation
16
sumoylation stat1
16
stat1
10
mapk-induced ser727
8
ser727
8
phosphorylation ser727
8
stat1 sumoylation
8
phosphorylation
7
sumoylation
7
phosphorylation promotes
4

Similar Publications

Objectives: To explore the active components that mediate the therapeutic effect of on psoriasis and their therapeutic mechanisms.

Methods: TCMSP, TCMIP, PharmMapper, Swiss Target Prediction, GeneCards, OMIM and TTD databases were searched for the compounds in and their targets and the disease targets of psoriasis. A drug-active component-target network and the protein-protein interaction network were constructed, and DAVID database was used for pathway enrichment analysis.

View Article and Find Full Text PDF

CD34+ orbital fibroblasts contribute to the pathogenesis of thyroid eye disease via miR-182-5p.

J Clin Endocrinol Metab

December 2024

Department of Ophthalmology, Shanghai Ninth People's Hospital, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, and Center for Basic Medical Research and Innovation in Visual System Diseases of Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shanghai, 200001, China.

Context: CD34+ orbital fibroblasts (OFs) play a pathogenic role in thyroid eye disease (TED). Several micro (mi)RNAs have been shown to promote TED progression.

Objective: This study aims to explore the regulatory effect of miRNAs on CD34+ OFs, to find potential therapeutic target.

View Article and Find Full Text PDF

Hypoxia Microenvironment Preconditioning Attenuated Myocardial Ischemia-Reperfusion Injury via Stc1-Mediating Cardiomyocyte Self-Protection and Neutrophil Polarization.

Adv Sci (Weinh)

December 2024

Department of Cardiology, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, 510515, China.

Ischemic preconditioning (IPC) therapy application to attenuate myocardial ischemia-reperfusion (MI/R) injury in clinical practice remains challenging. The secretome, derived from hypoxia-preconditioned cardiomyocytes (SHPC), potentially mimics the IPC microenvironment and facilitates IPC clinical translation. This study aims to determine whether SHPC can be a feasible alternative to IPC for attenuating MI/R injury, and to identify the functional factor of SHPC.

View Article and Find Full Text PDF

CDK8 inhibitor KY-065 rescues skeletal abnormalities in achondroplasia model mice.

Biochim Biophys Acta Mol Basis Dis

December 2024

Department of Bioactive Molecules, Pharmacology, Gifu Pharmaceutical University, Gifu 501-1196, Japan; United Graduate School of Drug Discovery and Medical Information Sciences, Gifu University, Gifu 501-1196, Japan; Center for One Medicine Innovative Translational Research (COMIT), Division of Innovative Modality Development, Gifu University, Gifu 501-1196, Japan. Electronic address:

Article Synopsis
  • CDK8 is essential for bone health, and its inhibitor KY-065 has shown potential in preventing postmenopausal osteoporosis in mice.
  • KY-065 has also been found to improve bone growth and chondrogenesis in a mouse model of achondroplasia (the most common form of genetic dwarfism), by targeting the STAT1 signaling pathway without affecting MAPK activation.
  • The results suggest that CDK8 in chondrocytes could be a new target for treatment, with KY-065 emerging as a promising drug for achondroplasia.
View Article and Find Full Text PDF

Background: The transcription factor Signal Transducer and Activator of Transcription 3 (STAT3) plays a role in carcinogenesis and is involved in processes, such as proliferation, differentiation, drug resistance and immunosuppression. STAT3 can be activated by phosphorylation of tyrosine at position 705 (pSTAT3) or serine at 727 (pSTAT3). High expression levels of pSTAT3 are implicated in advanced stages of prostate cancer (PCa) and are known to interact with the androgen receptor signaling pathway.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!